(PWRM, OXGN, NATR, ACHN) Stock under Consideration by Stock-PR.com

<p align="center">Stock-PR Reporting</p>
<p align="center"><a title="Stock-PR website" href="stock-pr.com&quot; target="_blank"><img class="alignnone size-full wp-image-2414" title="stockpr_logo-site" alt="stockpr_logo-site" src="stock-pr.com/img/stockpr_logo-site.jpg&quot; /></a></p>
<p align="center"> </p>
<p align="center"><strong><a title="free stock alerts, best stock alerts, hot stock alerts, stock picks, best stock picks, free stock picks" href="pennyomega.com/?page_id=835&quot;></a></strong></p>
<p align="center"><strong><span style="COLOR: black">FREE Daily Stock Alerts From Stock-PR.com</span></strong></p>
<p style="TEXT-ALIGN: center"> </p>
<p align="center"><a title="free stock alerts, best stock alerts, hot stock alerts, stock picks, best stock picks, free stock picks" href="stock-pr.com/?page_id=1085&quot;></a></p>
<p align="center"><span style="COLOR: black"><strong><span style="COLOR: black"><strong><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><a title="stock-pr sign up" href="stock-pr.com/signup&quot; target="_blank"><img height="90" alt="chartstockalert" src="pennyomega.com/img/chartstockalert.jpg&quot; width="360" /></a></span></span></strong></span></strong></span></p>
<p align="center"> </p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black"><strong><img style="WIDTH: 176px; HEIGHT: 76px" height="63" alt="power3" hspace="0" src="pennyomega.com/img/power3.png&quot; width="152" align="bottom" border="0" /> Power3 Medical Products, Inc. (OTC:PWRM)<br />
<br /></strong>The NuroPro Blood Test is Power3's medical diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.<br />
<br />
The immediate cause of Parkinson's disease is the destruction of brain cells in a part of the brain known as the substantia nigra (SN). The substantia nigra controls many types of muscular movement by releasing a neurotransmitter called dopamine. A neurotransmitter is a chemical that transports electrical signals between brain cells. Dopamine is needed to carry nerve messages from one brain cell to another.</font></span></span></span></span></p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black"><strong>Power3 Medical Products, Inc</strong>. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.<br />
<br />
Please visit Power3 Medical Products, Inc website</font> <a href="www.power3medical.com&quot;><font color="black">www.power3medical.com&lt;/font></a><font color="black">.<br />
<br />
*******************************************************************************<br />
<br />
<strong>Oxigene Inc. (Nasdaq:OXGN)</strong> will report first quarter 2011 results on Thursday, May 12, 2011. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm EDT (1:30 p.m. PDT). To listen to a live or an archived version of the audio webcast, please log on to the Company's website,</font> <a href="www.oxigene.com&quot;><font color="black">oxigene.com&lt;/font></a><font color="black">. Under the "Investors" tab, select the link to "Events &amp; Presentations." OXiGENE's earnings conference call can also be heard live by dialing (888) 841-3431 in the United States and Canada, and +1 (678) 809-1060 for international callers, five minutes prior to the beginning of the call. A replay will be available starting at 7:30 p.m. EDT, (4:30 p.m. PDT) on May 12, 2011 and ending at midnight EST (9:00 p.m. PDT) on Wednesday, May 18, 2011. To access the replay, please dial (800) 642-1687 if calling from the United States or Canada, or +1 (706) 645-9291 from international locations. Please refer to replay pass code 66014001.<br />
<br />
OXiGENE, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat cancer and eye diseases in the United States.<br />
<br />
*********************************<br />
<br />
<strong>Nature's Sunshine Products Inc. (Nasdaq:NATR)</strong> reported consolidated financial results for the first quarter ended March 31, 2011. For the First Quarter of 2011: Net sales were $92.8 million, compared with $86.8 million in the same quarter a year ago, an increase of 7.0 percent. Operating income from continuing operations was $7.6 million, compared with $0.6 million in the same quarter a year ago, an increase of 1,237.0%. EBITDA, defined here as net income before taxes, depreciation and amortization, other income and adjusted to include share-based compensation expense, was $8.8 million, compared with $1.8 million in the same quarter a year ago, an increase of 398.7 percent.<br />
<br />
Nature's Sunshine Products, Inc., together with its subsidiaries, engages in the manufacture and marketing of nutritional and personal care products worldwide.<br />
<br />
*********************************<br />
<br />
<strong>Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN)</strong> reported financial results for the three months ended March 31, 2011. For the first quarter of 2011, the Company reported a net loss of $10.1 million or $0.17 per share, compared with a net loss of $5.6 million or $0.16 per share for the first quarter of 2010. Cash, cash equivalents and marketable securities as of March 31, 2011 were $46.4 million. "Achillion achieved a number of significant pipeline milestones during the early part of 2011, including the release of robust RVR results for ACH-1625 and the recent submission of two IND applications that pave the way for the start of clinical trials with ACH-2684, our pan-genotypic protease inhibitor, and for ACH-2928, the most advanced candidate from our NS5A development program," commented Michael D. Kishbauch, President and Chief Executive Officer of Achillion.<br />
<br />
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases.</font><br /></span></span></span></span></p>
<p align="center"> </p>
<p align="center"> </p>
<p align="center">**************************************************************</p>
<p align="center"><strong>THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!</strong></p>
<p><strong><font color="blue"><font color="red">Disclaimer:</font> Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (<font color="red">Read more at <a href="stock-pr.com/?page_id=40&quot; target="_blank"><font color="red">stock-pr.com/disclaimer&lt;/font></a></font>).</font></strong><span style="COLOR: red"><span style="COLOR: red"><strong><font color="blue">Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. <font color="red">Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).<br /></font></font></strong></span></span></p>
<p> </p>
<p> </p>
<p align="center">Sign Up For Free Stock Alerts At <a href="stock-pr.com/signup&quot; target="_blank">stock-pr.com/signup&lt;/a></p>
<p align="center"><a href="www.crownequityholdings.com&quot; target="_blank"><img alt="stock-pr.com/img/stock-pr_buscard.jpg&quot; src="stock-pr.com/img/stock-pr_buscard.jpg&quot; /></a></p>